Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF Effect on Intrathecal Immune Activation
NCT02771054Phase 4Completed
- Sponsor
- University of Gothenburg
- Start
- May 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of Gothenburg. Primary endpoints: Reduction of CSF immune activation as measured by CSF neopterin at 12 months, Reduction of CSF immune activation as measured by CSF beta-2-microglobulin at 12 months and 1 more. Started May 2016; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02771054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771054.